Chemomab Therapeutics Reports 2023 Financials & Corporate Update

TL;DR

Chemomab dropped its Q4 2023 earnings and an update. Check the 6-K.

AI Summary

Chemomab Therapeutics Ltd. announced its financial results for the year ended and fourth quarter of 2023 on March 7, 2024. The company, formerly known as Anchiano Therapeutics Ltd. and BioCancell Ltd., is a foreign private issuer filing a Form 6-K report. The filing provides a corporate update alongside the financial results.

Why It Matters

This filing provides investors with the latest financial performance and strategic direction of Chemomab Therapeutics, a company operating in the pharmaceutical preparations sector.

Risk Assessment

Risk Level: low — This is a routine financial results and corporate update filing (6-K) with no new material events or significant financial changes disclosed.

Key Players & Entities

• Chemomab Therapeutics Ltd. (company) — Registrant
• Anchiano Therapeutics Ltd. (company) — Former company name
• BioCancell Ltd. (company) — Former company name
• March 7, 2024 (date) — Date of press release and filing
• 2023 (date) — Fiscal year for financial results

FAQ

Filing Documents

• zk2431109.htm (6-K) — 10KB
• exhibit_99-1.htm (EX-99.1) — 152KB
• image00001.jpg (GRAPHIC) — 21KB
• 0001178913-24-000856.txt ( ) — 192KB

From the Filing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number 001-38807 CHEMOMAB THERAPEUTICS LTD. (Translation of registrant's name into English) Kiryat Atidim, Building 7, Tel-Aviv, Israel (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F. Form 20-F Form 40-F EXPLANATORY NOTE On March 7, 2024, Chemomab Therapeutics Ltd. (the "Registrant") issued a press release titled "Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update", a copy of which is furnished as Exhibit 99.1 herewith. The financial information included in the consolidated balance sheets and consolidated statements of operations contained in the press release attached as Exhibit 99.1 to this Report on Form 6-K is hereby incorporated by reference into the Registrant's Registration Statements on Form F-3 (File No. 333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868). EXHIBIT INDEX Exhibit Description 99.1 Press release, dated March 7, 2024, titled "Chemomab Therapeutics Announces Year End and Fourth Quarter 2023 Financial Results and Provides a Corporate Update" SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. CHEMOMAB THERAPEUTICS LTD. Date: March 7, 2024 By: /s/ Sigal Fattal Sigal Fattal Chief Financial Officer

View Full Filing

View this 6-K filing on SEC EDGAR